PubMed Health⌕ Search

Biomedical subjects

Krishna Komanduri

Publications and source records attributed to Krishna Komanduri.

7 recordsLinked to original sources
PubMed2006

Abdominal organ motion measured using 4D CT.

PURPOSE: To measure respiration-induced abdominal organ motion using four-dimensional computed tomography (4D CT) scanning and to examine the organ paths. METHODS AND MATERIALS: During 4D CT scanning, consecutive CT images are acquired of the patient at each couch position. Simultaneously, the patient's respiratory pattern is recorded using an external marker block taped to the patient's abdomen. This pattern is used to retrospectively organize the CT images into multiple three-dimensional images, each representing one breathing phase. These images are analyzed to measure organ motion between each phase. The displacement from end expiration is compared to a displacement limit that represents acceptable dosimetric results (5 mm). RESULTS: The organs measured in 13 patients were the liver, spleen, and left and right kidneys. Their average superior to inferior absolute displacements were 1.3 cm for the liver, 1.3 cm for the spleen, 1.1 cm for the left kidney, and 1.3 cm for the right kidney. Although the organ paths varied among patients, 5 mm of superior to inferior displacement from end expiration resulted in less than 5 mm of displacement in the other directions for 41 of 43 organs measured. CONCLUSIONS: Four-dimensional CT scanning can accurately measure abdominal organ motion throughout respiration. This information may result in greater organ sparing and planning target volume coverage.

Abdomen↗
PubMed2005

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

Allogeneic progenitor cell transplantation is the only curative therapy for patients with refractory acute myelogenous leukemia or myelodysplastic syndromes. To identify prognostic factors in these patients, we performed a retrospective analysis of transplantation outcomes. Patients were selected if they had undergone an allogeneic transplantation between January 1988 and January 2002 and were not in remission or first untreated relapse at the time of transplantation. A total of 135 patients were identified. The median age was 49.5 years (range, 19-75 years). At the time of transplantation, 39.3% of patients had not responded to induction therapy, 37% had not responded to first salvage therapy, and 23.7% were beyond first salvage. Forty-one patients (30%) received unrelated donor progenitor cells. Eighty patients (59%) received either a reduced-intensity or a nonmyeloablative regimen. A total of 104 (77%) of 135 patients died, with a median survival time of 4.9 months (95% confidence interval, 3.9-6.6 months). The median progression-free survival was 2.9 months (95% confidence interval, 2.5-4.2 months). A Cox regression analysis showed that Karnofsky performance status, peripheral blood blasts, and tacrolimus exposure during the first 11 days after transplantation were predictive of survival. These data support the use of allogeneic transplantation for patients with relapsed or refractory acute myelogenous leukemia/myelodysplastic syndromes and suggest that optimal immune suppression early after transplantation is essential for long-term survival even in patients with refractory myeloid leukemias.

Adult↗
PubMed2005

Determination of CT-to-density conversion relationship for image-based treatment planning systems.

The implementation of tissue inhomogeneity correction in image-based treatment planning will improve the accuracy of radiation dose calculations for patients undergoing external-beam radiotherapy. Before the tissue inhomogeneity correction can be applied, the relationship between the computed tomography (CT) value and density must be established. This tissue characterization relationship allows the conversion of CT value in each voxel of the CT images into density for use in the dose calculations. This paper describes the proper procedure of establishing the CT value to density conversion relationship. A tissue characterization phantom with 17 inserts made of different materials was scanned using a GE Lightspeed Plus CT scanner (120 kVp). These images were then downloaded into the Eclipse and Pinnacle treatment planning systems. At the treatment planning workstation, the axial images were retrieved to determine the CT value of the inserts. A region of interest was drawn on the central portion of the insert and the mean CT value and its standard deviation were determined. The mean CT value was plotted against the density of the tissue inserts and fitted with bilinear equations. A new set of CT values vs. densities was generated from the bilinear equations and then entered into the treatment planning systems. The need to obtain CT values through the treatment planning system is very clear. The 2 treatment planning systems use different CT value ranges, one from -1024 to 3071 and the other from 0 to 4096. If the range is correct, it would result in inappropriate use of the conversion curve. In addition to the difference in the range of CT values, one treatment planning system uses physical density, while the other uses relative electron density.

Densitometry↗
PubMed2005

Prescription dose in permanent (131)Cs seed prostate implants.

Recently, 131Cs seeds have been introduced for prostate permanent seed implants. This type of seed has a relatively short half-life of 9.7 days and has its most prominent emitted photon energy peaks in the 29-34 keV region. Traditionally, 145 and 125 Gy have been prescribed for 125I and 103Pd seed prostate implants, respectively. Since both the half-life and dosimetry characteristics of 131Cs seed are quite different from those of 125I and 103Pd, the appropriate prescription dose for 131Cs seed prostate implant may well be different. This study was designed to use a linear quadratic radiobiological model to determine an appropriate dose prescription scheme for permanent 131Cs seed prostate implants. In this model, prostate edema was taken into consideration. Calculations were also performed for tumors of different doubling times and for other related radiobiological parameters of different values. As expected, the derived prescription dose values were dependent on type of tumors and types of edema. However, for prostate cancers in which tumor cells are relatively slow growing and are reported to have a mean potential doubling time of around 40 days, the appropriate prescription dose for permanent 131Cs seed prostate implants was determined to be: 127(+5)(-12)Gy if the experiences of 125I seed implants were followed and 121(+0)(-3)Gy if the experiences of 103Pd followed.

Body Burden↗
PubMed2004

Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.

Hematopoietic stem cell transplantation has evolved as a central treatment modality in the management of different hematologic malignancies. Despite adequate posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in the hematopoietic stem cell transplantation setting, even in patients who receive human leukemic antigen (HLA) identical sibling grafts. Up to 30% of the recipients of stem cells or bone marrow transplantation from HLA-identical related donors and most patients who receive cells from other sources (matched-unrelated, non-HLA-identical siblings, cord blood) will develop > Grade 2 acute GVHD despite immunosuppressive prophylaxis. Thus, GVHD continues to be a major limitation to successful hematopoietic stem cell transplantation. In this review, the authors summarize the most current knowledge on the pathophysiology, clinical manifestations, and management of this potentially life-threatening transplantation complication.

Acute Disease↗
PubMed2002

Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions.

The graft-versus-leukemia (GVL) effect associated with allogeneic blood and marrow transplantation has largely been a clinically described phenomenon until recently. We are beginning to understand the cellular and molecular nature of GVL, and in this review the authors highlight the potential for self-antigen-specific T lymphocytes to contribute to GVL. The authors focus on myeloid tissue-restricted proteins as GVL target antigens in CML and AML, and in particular on proteinase 3 and other azurophil granule proteins as targets for both autologous and allogeneic T-cell responses. Finally, the authors discuss myeloid self-antigen-directed alloreactivity in the context of our evolving understanding of the critical molecular determinants of allogeneic T-cell recognition. By altering T-cell receptor affinity, peptide specificity can be maintained and the potency of immunity can be enhanced in the MHC-mismatched setting.

Antigens, Differentiation↗